Top

Published in:

01-10-2020 | Tuberculosis | Review Article

Multi-Drug Resistant and Extensively-Drug Resistant Tuberculosis

Authors: Ira Shah, Vishrutha Poojari, Himali Meshram

Published in: Indian Journal of Pediatrics | Issue 10/2020

Abstract

India is one of the high burden countries for tuberculosis (TB) including multi-drug resistant TB (MDR-TB) and extensively-drug resistant (XDR) TB. Drug-resistant (DR) TB has threatened the TB care and is a major health problem in many countries; treatment of DR TB has been difficult requiring use of reserve or second-line drugs, cost factors, has extensive side-effect profile and long duration of treatment. Treatment in MDR-TB are increasingly becoming individualised mainly due to preference for oral over injectable, results of drug susceptibility testing (DST), population resistance levels, history of previous TB treatment, drug tolerability and drug-to-drug interactions. Bedaquilline (BDQ) and delaminid (DLM) are new drugs available for treatment of these patients. World Health Organization (WHO) recommends use of BDQ in more than 15 y (>15 kg) patients only. Under Revised National Tuberculosis Control Programme (RNTCP) the use of this drug is recommended for patients older than 18 y only. Under RNTCP, the use of DLM is approved in children 6 y and above. Pediatric MDR/XDR TB treatment outcome with newer anti-TB drugs and regimen is lacking. Children when treated with individualized regimens have improved survival.

World Health Organisation. Global Tuberculosis Report 2018. Geneva: World Health Organization; 2018. Available at: https://www.who.int/tb/publications/global_report/en/. Accessed 29 July 2019.

TB facts. TB Statistics India - National, Treatment Outcome, State. 2018. Available at: https://www.tbfacts.org/tb-statistics-india/. Accessed 28 July 2019.

TB facts. Multi Drug Resistant TB - What is MDR, Statistics, Treatment. 2018. Available at: https://www.tbfacts.org/multi-drug-resistant-tb/. Accessed 28 July 2019.

Dodd PJ, Sismanidis C, Seddon JA. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. Lancet Infect Dis. 2016;16:1193–201.CrossRef

Shah MA, Shah I. Increasing prevalence of pediatric drug-resistant tuberculosis in Mumbai, India and its outcome. Pediatr Infect Dis J. 2018;37:1261–3.CrossRef

Seaworth BJ, Griffith DE. Therapy of multidrug-resistant and extensively drug-resistant tuberculosis. Microbiol Spectr. 2017;5. https://doi.org/10.1128/microbiolspec.TNMI7-0042-2017.

Sharma P, Lalwani J, Pandey P, Thakur A. Factors associated with the development of secondary multidrug-resistant tuberculosis. Int J Prev Med. 2019;10:67.CrossRef

Shah I. Drug resistant tuberculosis. In: Shah I, editor. Tuberculosis, 2^nd ed. Mumbai: Pediatric Oncall; 2016. p. 88–106.

Pontali E, Raviglione MC, Migliori GB; The Writing Group Members of the Global TB Network Clinical Trials Committee. Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives. Eur Respir Rev. 2019;28:190035.

10.

TB facts. Genexpert Test – TB Diagnosis, TB Resistance Testing, CB-NAAT. 2018. Available at: https://www.tbfacts.org/genexpert/. Accessed 29 July 2019.

11.

Microbeonline Medical Microbiology Guide [Internet]. Acharya T: GenXpert MTB/Rif Assay: Principle, Procedure, Results and Interpretations. 2016. Available at: https://microbeonline.com/genexpert-mtbrif-assay-principle-procedure-results-interpretations/. Accessed 28 July 2019.

12.

Denkinger CM, Schumacher SG, Boehme CC, Dendukuri N, Pai M, Steingart KR. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2014;44:435–46.CrossRef

13.

Cephid [Internet]. 2017 Launch of New TB Test Ultra Backed by WHO Recommendation 2017. Available at: https://www.cepheid.com/de/uber-uns/news-events/press-releases/216-2017-launch-of-new-tb-test-ultra-backed-by-who-recommendation. Accessed 28 July 2019.

14.

Chakravorty S, Simmons AM, Rowneki M, et al. The new xpert MTB/RIF ultra: improving detection of mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing. MBio. 2017;8:e00812–7.CrossRef

15.

TB Facts. Information about Tuberculosis [Internet]. Kanabus A: Drug Susceptibility Testing - Molecular Tests, Line Probe Assay. 2018. Available at: https://www.tbfacts.org/drug-susceptibility. Accessed 20 July 2019.

16.

World Health Organisation (WHO). The Use of Next-Generation Sequencing Technologies for the Detection of Mutations Associated with Drug Resistance in Mycobacterium tuberculosis Complex: Technical Guide. Available at: https://apps.who.int/iris/handle/10665/274443. Accessed 8 August 2019.

17.

Georghiou SB, Magana M, Garfein RS, Catanzaro DG, Catanzaro A, Rodwell TC. Evaluation of genetic mutations associated with mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One. 2012;7:e33275.CrossRef

18.

The Union. Field Guide for the Management of Drug-Resistant Tuberculosis- 2018. Available at: https://www.theunion.org/what-we-do/publications/technical/english/TheUnion_DR-TB-Guide.pdf. Accessed 8 August 2019.

19.

Ministry of Health & Family Welfare. Central Tuberculosis Division. Guideline for Programmatic Management of Drug Resistant Tuberculosis in India 2017. India: Available at: https://tbcindia.gov.in/index1.php?lang=1&level=2&sublinkid=4780&lid=3306. Accessed 18 July 2019.

20.

Parsons LM, Somoskövi A, Gutierrez C, et al. Laboratory diagnosis of tuberculosis in resource poor countries: challenges and opportunities. Clin Microbiol Rev. 2011;24:314–50.CrossRef

21.

TB Facts. Information about Tuberculosis [Internet]. Kanabus A: TrueNat TB Test - Diagnosis and Resistance Testing 2018. Available at: https://www.tbfacts.org/truenat/. Accessed 20 July 2019.

22.

Colman RE, Schupp JM, Hicks ND, et al. Detection of low-level mixed-population drug resistance in mycobacterium tuberculosis using high fidelity amplicon sequencing. PLoS One. 2015;10:e0126626.CrossRef

23.

World Health Organisation (WHO). Policy Guidance on Drug-Susceptibility Testing (DST) of Second Line Antituberculosis Drugs. Available at: https://www.who.int/tb/publications/2008/whohtmtb_2008_392/en/. Accessed 8 August 2019.

24.

Bahuguna A, Rawat DS. An overview of new antitubercular drugs, drug candidates, and their targets. Med Res Rev. 2020;40:263–92.CrossRef

25.

World Health Organization. WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment 2019? Available at: https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf. Accessed 8 July 2019.

26.

Ministry of Health & Family Welfare. Central Tuberculosis Division. Guideline for Use of Bedaquiline in RNTCP Through Conditional Access Under Programmatic Management of Drug Resistant Tuberculosis in India. Available at URL: https://www.tbcindia.gov.in/index1.php?lang=1&level=2&sublinkid=4682&lid=3248. Accessed 29 July 2019.

27.

Ministry of Health & Family Welfare. Central Tuberculosis Division. Guidelines for use of Delamanid for treatment of DR-TB in India, 2018. India. Available at: https://tbcindia.gov.in/showfile.php?lid=3343. Accessed 25 July 2019.

28.

TB Facts. Information about Tuberculosis [Internet]. Kanabus A: Treatment of Drug Resistant TB - Injectable Drugs, Cost. 2018. Available at: https://www.tbfacts.org/treatment-of-drug-resistant-tb/ Accessed 29 July 2019.

29.

Arbex MA, Varella Mde C, Siqueira HR, Mello FA. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations - part 2: second line drugs. J Bras Pneumol. 2010;36:641–56.CrossRef

30.

Arbex MA, Varella Mde C, Siqueira HR, Mello FA. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations - part 1: first-line drugs. J Bras Pneumol. 2010;36:626–40.CrossRef

31.

World Health Organization (WHO). Rapid Communication: Key Changes to Treatment of Multidrug- and Rifampicin-Resistant Tuberculosis (MDR/RR-TB). 2018. Available at: http://www.who.int/tb/publications/2018/WHO. Accessed 25 July 2019.

32.

Dalal A, Pawaskar A, Das M, et al. Resistance patterns among multidrug resistant tuberculosis patients in greater metropolitan Mumbai: trends over time. PLoS One. 2015;10:e0116798.CrossRef

33.

Shah I, Shah F. Changing prevalence and resistance patterns in children with drug-resistant tuberculosis in Mumbai. Paediatr Int Child Health. 2017;37:135–8.CrossRef

34.

Osman M, Harausz EP, Garcia-Prats AJ, et al; Collaborative Group for Meta-Analysis of Paediatric Individual Patient Data in MDR TB. Treatment outcomes in global systematic review and patient meta-analysis of children with extensively drug-resistant tuberculosis. Emerg Infect Dis. 2019;25:441–50.

35.

Loveday M, Sunkari B, Marais BJ, Master I, Brust JC. Dilemma of managing asymptomatic children referred with ‘culture-confirmed’ drug-resistant tuberculosis. Arch Dis Child. 2016;101:608–13.CrossRef

Title: Multi-Drug Resistant and Extensively-Drug Resistant Tuberculosis
Authors: Ira Shah
Vishrutha Poojari
Himali Meshram
Publication date: 01-10-2020
Publisher: Springer India
Keywords: Tuberculosis
Moxifloxacin
Amikacin
Tuberculosis
Linezolid
Published in: Indian Journal of Pediatrics / Issue 10/2020
Print ISSN: 0019-5456
Electronic ISSN: 0973-7693
DOI: https://doi.org/10.1007/s12098-020-03230-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Multi-Drug Resistant and Extensively-Drug Resistant Tuberculosis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2020

Serum Cathelicidin Concentrations in Healthy Rural Indian School Going Children

Biomarkers for Prognostication in Hypoxic-Ischemic Encephalopathy

Distal Arthrogryposis: A Clue to the Etiology of Neonatal Cholestasis

Familial Hemophagocytic Lymphohistiocytosis Type 3

Vaccine Against Covid-19 Disease – Present Status of Development

Congenital Cytomegalovirus and Zika Infections